Sertoli-Leydig cell tumors are rare sex cord-stromal tumors. These tumors account for less than 0.5% of all ovarian tumors. Because these tumors appear predominantly in young women (between the age of 30 and 40) and are bilateral in less than 1% of cases, conservative removal of the tumor and adjacent fallopian tube is justifiable. Recently, we experienced a case of successful laparoscopic surgical staging in patient of Sertoli-Leydig cell tumor which was previously incompletely evaluated in local OBGY clinic. There are no solid data to suggest that usefulness and risk of laparoscopic surgical staging and adjuvant therapy with stage I disease of these tumors until now. So we present it with a brief review of literature.
Fallopian Tubes ; Female ; Humans ; Sertoli-Leydig Cell Tumor* ; Sex Cord-Gonadal Stromal Tumors

The Sertoli-Leydig cell tumor is a rare sex cord stromal tumor of the ovary. It is the most common type of all virillizing ovarian tumors, accounting for less than 0.5% of all primary ovarian neoplasm. Recently, we experienced two cases of intermediately differentiated Sertoli-Leydig cell tumor with amenorrhea and so we present it with brief review of literature.
Amenorrhea ; Female ; Ovarian Neoplasms ; Ovary* ; Sertoli-Leydig Cell Tumor* ; Sex Cord-Gonadal Stromal Tumors

The Sertoli-Leydig cell tumor is a rare sex cord stromal tumor of the ovary. It is the most common type of all virillizing ovarian tumors, accounting for less than 0.5% of all primary ovarian neoplasm. Recently, we experienced two cases of intermediately differentiated Sertoli-Leydig cell tumor with amenorrhea and so we present it with brief review of literature.
Amenorrhea ; Female ; Ovarian Neoplasms ; Ovary* ; Sertoli-Leydig Cell Tumor* ; Sex Cord-Gonadal Stromal Tumors

The Sertoli-Leydig cell tumor is a rare sex cord stromal tumor of the ovary, accounting for less than 0.5% of all primary ovarian neoplasm. This tumor is the most common type of all virilizing ovarian tumors. However, only one-third of patients develop virilization. Recently, we experienced a case of intermediately differentiated Sertoli-Leydig cell tumor with amenorrhea and so we present it with brief review of literature.
Amenorrhea ; Female ; Humans ; Ovarian Neoplasms ; Ovary ; Sertoli-Leydig Cell Tumor* ; Sex Cord-Gonadal Stromal Tumors ; Virilism

Unclassified type occupies about 5 to 10 percent of all ovarian sex cord stromal tumors. Diagnosis is very difficult and subjective because tumors show insufficient differentiation to ovarian or testicular line or display insufficient findings to diagnose as a gynandroblastoma in spite of divergent differentiation. To our knowledge sixty-two cases have been reported in the pathology literatures as yet. The behavior of this group of tumors has not been adequately studied but is similar to granulose cell tumors or Sertoli-Leydig cell tumors. We present a case of unclassified sex cord-stromal tumor which has been experienced in our hospital with brief review of the literature.
Diagnosis ; Female ; Ovary ; Pathology ; Sertoli-Leydig Cell Tumor ; Sex Cord-Gonadal Stromal Tumors*

Cell Differentiation ; Female ; Humans ; Middle Aged ; Sertoli-Leydig Cell Tumor ; pathology ; Sex Cord-Gonadal Stromal Tumors ; pathology

Ovarian Sertoli-Leydig cell tumors are rare sex cord-stromal tumors, accounting for less than 1% of ovarian tumors. Majority of these tumors are benign and unilateral, only 3-5% are bilateral. These patients present with clinical features of virilization due to excessive secretion of testosterone from the tumor, however 50% may have no endocrine symptoms. We report a case of poorly differentiated Sertoli-Leydig cell tumour in a woman diagnosed during routine investigation of infertility. She had two spontaneous successful pregnancies after tumor excision laparoscopically.
Accounting ; Female ; Humans ; Infertility ; Laparoscopy ; Ovary ; Pregnancy ; Sertoli-Leydig Cell Tumor ; Sex Cord-Gonadal Stromal Tumors ; Testosterone ; Virilism

OBJECTIVETo analyze the clinicopathological features of ovarian tumors with endocrine function.

METHODSTwenty-four cases of ovarian tumor with endocrine manifestation were collected from the hospital. Their clinical presentation and histopathologic features were reviewed, along with a panel immunohistochemistry stainings (EnVision method). The antibodies were AE1/AE3, epithelial membrane antibody (EMA), alpha-inhibin, calretini and smooth myoglobin (SMA).

RESULTSThe main clinical endocrinological manifestations were related to an excess production of sex steroids. Histologically, the principle histological subtype of these tumors was ovarian sex cord-stroma tumors, including 13 cases ovarian type (8 granulosa cell tumors, 2 thecofibromas, 3 sclerosing stromal tumors), 7 cases testicular type (1 sertoli cell tumors, 5 sertoli-Leydig cell tumors, 1 Leydig cell tumor, and 2 cases of steroid cell tumor (NOS). Another 2 cases were ovarian epithelial tumors. Grossly, 50% (11/22) ovarian sex cord-stromal tumors were less than 5 cm in diameter. However, 4 tumors were quite larger, up to 18 cm in diameter. Most of these tumors were solid or solid-cystic and their cut surfaces were brown, pink, yellow or grey in color. The 2 primary ovarian epithelial tumors were larger, being 12 cm and 14 cm in diameter, respectively. Immunohistochemically, ovarian sex cord-stromal tumors showed positive staining for alpha-inhibin in all cases (22/22) and for calretinin in majority cases (18/22), and that the intensity of reactivity correlated with the degree of tumor differentiation. The non-neoplastic, luteinized stromal cells in 2 ovarian primary epithelial tumors also showed positive staining. Five cases of fibrothecomas and sclerosing stroma tumors were all positive for SMA. Although 6 of the 22 ovarian sex cord-stromal tumors were AE1/AE3 positive, all were EMA negative.

CONCLUSIONSMost endocrinological syndromes in ovarian neoplasia reflect an overproduction of sex steroids, but the clinical manifestations do not correlate with the tumor histological subtypes. Most functional ovarian tumors are sex cord-stromal tumors and are usually of small to medium in size, but few are larger or giant. The size of the tumor does not correlate with the duration and the degree of clinical manifestations. Ovarian tumors of non-sex cord-stromal type may also be clinically functional. The immunohistochemical results suggests that alpha-inhibin and/or calretinin expression are useful markers in support of a diagnosis of sex cord-stromal tumor of the ovary. Although some of these tumors are AE1/AE3 positive, EMA negativity may be useful for the differential diagnosis with epithelial ovarian tumors.

Adolescent ; Adult ; Aged ; Biomarkers, Tumor ; analysis ; Calbindin 2 ; Female ; Gonadal Steroid Hormones ; secretion ; Granulosa Cell Tumor ; chemistry ; pathology ; secretion ; Humans ; Immunohistochemistry ; Inhibins ; analysis ; Middle Aged ; Ovarian Neoplasms ; chemistry ; pathology ; secretion ; S100 Calcium Binding Protein G ; analysis ; Sertoli-Leydig Cell Tumor ; chemistry ; pathology ; secretion ; Sex Cord-Gonadal Stromal Tumors ; chemistry ; pathology ; secretion

Sertoli-Leydig cell tumors of the ovary are one of the sex cord-stromal tumors. They are very rare, account for less than 0.5% of all ovarian tumor. These tumors are almost unilateral, and occur predominantly at premenopausal state and rarely at postmenopausal and prepubertal. The most specific symptoms are virilization due to hyperandrogenism but it presents only in 40-50% of the patients, and vast majority of the patients complain for non-specific abdominal symptoms and menstrual disorder including vaginal bleeding. Prognosis and treatment modalities for Sertoli-Leydig cell tumors remain controversial as they are rare and only a few studies have been published. Treatment varies with patients age, tumor stage, and differentiation from unilateral salpingo-oophrectomy and total hysterectomy concomitant with pelvic lymph node dissection, and in occasion, adjuvant chemotherapy. Prognosis is generally favorable with 5-year survival rate of 70-90%. Recurrence is rare. We have experienced three cases of Sertoli-Leydig cell tumor, each of them showed different clinical presentation and histologic findings, so we present them with a brief review of literature.
Chemotherapy, Adjuvant ; Female ; Humans ; Hyperandrogenism ; Hysterectomy ; Lymph Node Excision ; Ovary ; Prognosis ; Recurrence ; Sertoli-Leydig Cell Tumor* ; Sex Cord-Gonadal Stromal Tumors ; Survival Rate ; Uterine Hemorrhage ; Virilism

No abstract available.
Sertoli-Leydig Cell Tumor*